<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endothelin (ET) receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> are of great potential clinical interest for the treatment pathological conditions associated with vasospasm, such as <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain>We developed for parenteral use a compound of a class of trifunctionalized heteroarylsulfonamide <z:chebi fb="0" ids="39447">pyrimidines</z:chebi> specially designed for high water solubility </plain></SENT>
<SENT sid="2" pm="."><plain>Ro 61-1790 [5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-<z:chebi fb="1" ids="16227">pyridine</z:chebi>-2-<z:chebi fb="0" ids="29214">sulfonic acid</z:chebi> 6-(2-hydroxy-<z:chebi fb="2" ids="42241">ethoxy</z:chebi>)-5-(2-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-phenoxy)-2-(2-1H-tetrazol-5-yl-+ ++pyri din-4-yl)-<z:chebi fb="0" ids="16898">pyrimidin</z:chebi>-4-ylamide] is a competitive ET <z:chebi fb="68" ids="48706">antagonist</z:chebi> with an affinity to <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor in the subnanomolar range </plain></SENT>
<SENT sid="3" pm="."><plain>It has a approximately 1000-fold selectivity for the <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> vs. the ETB receptor as assessed on functional assays (e.g., ET-1-induced <z:chebi fb="1" ids="24848">inositol</z:chebi>-1,4, 5-<z:chebi fb="0" ids="15266,18036">triphosphate</z:chebi> release or ET-1-induced intracellular calcium mobilization) </plain></SENT>
<SENT sid="4" pm="."><plain>Ro 61-1790 also had a high functional potency for inhibiting contraction induced by ET-1 on isolated rat aorta (<z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptors; pA2 = 9.5) or by sarafotoxin S6c on rat trachea (ETB receptors; pA2 = 6.4) </plain></SENT>
<SENT sid="5" pm="."><plain>In vivo, Ro 61-1790 inhibited the pressor effect of big ET-1 in pithed rats with an ID50 value of 0.05 mg/kg </plain></SENT>
<SENT sid="6" pm="."><plain>Intravenous bolus of Ro 61-1790 induced a long-lasting <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> effect in deoxycorticosterone <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> salt rats instrumented with telemetry </plain></SENT>
<SENT sid="7" pm="."><plain>In a double-<z:mp ids='MP_0001914'>hemorrhage</z:mp> canine model of SAH, Ro 61-1790 both prevented and reversed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in a dose-dependent manner </plain></SENT>
<SENT sid="8" pm="."><plain>In an established <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, 3 mg/kg Ro 61-1790 i.v. was half as efficacious as intrabasilar papaverine </plain></SENT>
<SENT sid="9" pm="."><plain>Ro 61-1790 (20 mg/kg/day) totally prevented the occurrence of vasospasm </plain></SENT>
<SENT sid="10" pm="."><plain>In summary, these data demonstrate that Ro 61-1790 is a potent and selective <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> suitable for parenteral use and potentially useful for preventing delayed ischemic deficit in patients with SAH </plain></SENT>
</text></document>